Unscripted the AMCP Podcast: Fixed-Duration Therapy, NCCN Guidelines, and Managed Care

This episode of Unscripted, the AMCP podcast, explores the transformative shift in chronic lymphocytic leukemia (CLL) treatment toward oral fixed-duration therapies, driven by updates to the 2026 NCCN guidelines. Corollos Hanna-Farndy, Director of Pharmacy at Minnesota Oncology and Assistant Professor at Mayo Clinic, discusses how combinations like venetoclax with BTK inhibitors (e.g., acalabrutinib, ibrutinib) or CD20 monoclonal antibodies (obinutuzumab, rituximab) are now preferred frontline options, offering patients the ability to stop treatment after about a year—marking a major departure from continuous BTK inhibitor therapy. The conversation highlights the growing role of minimal residual disease (MRD) testing in guiding treatment decisions, with MRD negativity linked to improved progression-free survival and the potential to discontinue therapy earlier. However, challenges remain in payer understanding, cost modeling, and access, especially as the Inflation Reduction Act impacts drug pricing for agents like ibrutinib and acalabrutinib. The discussion emphasizes shared decision-making between patients and providers, considering factors like age, comorbidities, and treatment burden, while also calling for value-based care partnerships and data collaboration across payers, providers, and pharma to navigate this evolving landscape. Key takeaways include: (1) Fixed-duration regimens are now standard in frontline CLL care, offering patients time off therapy and improved quality of life; (2) MRD testing is becoming increasingly important for personalizing treatment duration and improving outcomes; (3) Payers must evolve beyond short-term cost models to consider long-term savings from finite therapy; (4) The Inflation Reduction Act is reshaping formulary strategies, especially for Medicare, requiring reevaluation of step therapy and drug preferences; and (5) Shared decision-making and multidisciplinary collaboration are essential to optimize patient-centered care in CLL.